SEC Filing Summary
Issuer verification: The request identifies Kyntra Bio, Inc., but the supplied Form 10-Q is for FibroGen, Inc. (Nasdaq: FGEN). Confirm the intended issuer before relying on this summary.
Business context and reporting period
This unaudited Form 10-Q covers the quarter and six months ended June 30, 2022. FibroGen is a biopharmaceutical company developing pamrevlumab and roxadustat. Roxadustat was approved for CKD anemia in China, Europe, Japan, and other markets; pamrevlumab remained in late-stage clinical trials. The company relies on Astellas and AstraZeneca collaborations, including for roxadustat development and commercialization.
Financial performance and liquidity
Unless noted otherwise, amounts are in U.S. dollars.
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Total revenue | $29.8 million, versus $24.4 million in 2021 | $90.6 million, versus $62.8 million in 2021 |
| Operating costs and expenses | $108.0 million, down 32% | $231.8 million, down 13% |
| Operating loss | $78.2 million | $141.2 million |
| Net loss | $72.6 million; $0.78 per share | $135.8 million; $1.46 per share |
| Net cash used in operating activities | Not separately stated for the quarter | $41.5 million, versus $71.5 million in 2021 |
Revenue growth reflected higher China roxadustat product revenue and, for the first half, a $25.0 million Russian regulatory milestone from Astellas. Quarterly development and other revenue declined substantially year over year. Reported losses narrowed, while the company remained loss-making; the filing does not present a headline operating or net profit margin.
At June 30, 2022, cash and cash equivalents were $167.8 million, short- and long-term investments totaled $316.3 million, and accounts receivable were $33.6 million. Combined, these were $517.6 million, down $72.8 million from December 31, 2021. Current assets were $520.6 million and current liabilities $240.3 million. The filing reports $94.1 million of operating lease liabilities and $16.4 million of product development obligations; it does not identify conventional borrowings as a material balance-sheet item.
Management said available cash, investments, and receivables were expected to fund anticipated requirements for at least 12 months from issuance of the financial statements, while cautioning that additional capital may be needed thereafter. Cash and cash equivalents decreased by $3.5 million in the first half; investing activities provided $43.2 million, largely reflecting investment maturities, and financing activities used $0.8 million.
Material changes versus the prior comparable period
- Second-quarter revenue increased 22%; first-half revenue increased 44%. China product revenue rose 74% in the quarter and 47% in the half, to $23.3 million and $42.1 million, respectively.
- Development and other revenue fell 72% in the quarter and 50% in the half, mainly reflecting lower collaboration development billings, including reduced U.S. CKD-related co-development activity.
- Operating costs declined, in part because the prior-year period included a $25.0 million acquired in-process R&D charge and because of lower headcount and development/manufacturing costs. Cost of goods sold rose with higher product sales.
- First-half net cash used in operations improved year over year, while cash, cash equivalents, and investments together declined. Available-for-sale investments had $4.1 million of gross unrealized losses at June 30, 2022.
Outlook, commentary, risks, and unusual items
- Clinical outlook: Management expected topline results from pamrevlumab IPF trial ZEPHYRUS-1 and roxadustat MDS trial MATTERHORN in the first half of 2023; DMD trial LELANTOS-1 in the first half of 2023 and LELANTOS-2 in the second half of 2023; and pancreatic cancer trial LAPIS in the first half of 2024. The company did not plan to seek accelerated approval for LAPC after its interim analysis and said it would continue LAPIS to the overall-survival endpoint.
- Roxadustat: China sales volume was reported to be more than 80% higher in Q2 year over year, but lower National Reimbursement Drug List pricing affected net sales. FibroGen had not agreed with AstraZeneca on further funding for U.S. CKD-anemia development and did not expect most or all remaining U.S./RoW milestones. The company had discontinued recruitment in the China MDS Phase 3 study due to enrollment difficulties.
- Revenue uncertainty and accruals: Variable consideration for Astellas and AstraZeneca drug-product shipments remains uncertain. At June 30, $54.4 million was accrued for API and bulk drug product price true-ups; $43.3 million of amounts reclassified to accrued liabilities related to Astellas were expected to be paid in Q1 2023.
- Unusual tax-related adjustment: Evidence received from China’s tax authority after quarter-end confirmed a VAT exemption for certain 2020 IP transfers. The company recorded a $6.0 million reduction in other expenses, reduced accrued current liabilities by $8.2 million, and reduced other assets by $2.3 million.
- Legal and regulatory matters: A securities class action motion to dismiss was denied on July 15, 2022; derivative actions remain pending or stayed. The SEC had subpoenaed documents concerning roxadustat pooled cardiovascular safety data, and FibroGen said it was cooperating. The company reported no material legal accrual and could not estimate potential losses.
- Other exposures: Key risks include clinical-trial outcomes and enrollment, the U.S. roxadustat complete response letter, dependence on collaboration partners and manufacturers, China pricing and operating conditions, COVID-19 and Ukraine-related trial disruption, and potential financing needs. Management stated disclosure controls were effective as of June 30, 2022.
Most important facts for investors to verify
- Whether FibroGen, rather than Kyntra Bio, is the intended issuer and filing.
- Trial timelines, enrollment status, and forthcoming results for pamrevlumab and roxadustat, including any subsequent regulatory updates.
- China roxadustat sales trends, reimbursement pricing, profit-sharing economics, and the impact of currency movements.
- Whether collaboration funding or agreements with AstraZeneca or Astellas change, particularly for U.S. CKD-anemia development and drug-product true-ups.
- Cash runway assumptions, expected operating cash use, financing plans, and the timing and amount of disputed or estimated liabilities.
- Developments in the securities litigation, derivative claims, SEC investigation, and China VAT-related accounting treatment.